Benzinga · Aug 21, 2026
Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
https://www.sec.gov/Archives/edgar/data/1638097/000117891326004221/zk2635989.htm
EN
NASDAQ · ENTX
Entera Bio Ltd.
Healthcare · Biotechnology
$3.08
Down-$0.11 (-3.45%)
Updated Aug 28, 2026, 4:00 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 101.79M
- P/E ratio
- -41.77
- Dividend yield
- 0.00%
- 52-week range
- $0.91 – $4.20
- Volume
- 240.68K
- Avg. volume
- 154.41K
Price performance
ENTX price history
1M range · 21 trading sessions · Daily adjusted prices
ENTX closed at $3.08 after 21 trading sessions, up 4.41% for the selected period.
- Last close
- $3.08
- Period change
- +4.41%
- Period low
- $2.80
- Period high
- $3.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $3.20 | $3.41 | $3.03 | $3.08 | 240.68K |
| Aug 26, 2026 | $3.46 | $3.47 | $3.10 | $3.19 | 523.31K |
| Aug 25, 2026 | $3.42 | $3.5595 | $3.4052 | $3.47 | 429.97K |
| Aug 24, 2026 | $3.28 | $3.47 | $3.20 | $3.42 | 258.13K |
| Aug 21, 2026 | $3.22 | $3.34 | $3.14 | $3.23 | 441.3K |
| Aug 20, 2026 | $3.01 | $3.33 | $3.00 | $3.22 | 468.47K |
| Aug 19, 2026 | $2.93 | $3.2099 | $2.8797 | $3.11 | 696.06K |
| Aug 18, 2026 | $2.89 | $2.969 | $2.81 | $2.89 | 261.72K |
| Aug 17, 2026 | $2.83 | $2.97 | $2.82 | $2.90 | 305.88K |
| Aug 14, 2026 | $2.85 | $2.92 | $2.75 | $2.89 | 278.33K |
| Aug 13, 2026 | $2.78 | $2.92 | $2.76 | $2.87 | 246.48K |
| Aug 12, 2026 | $3.03 | $3.03 | $2.75 | $2.80 | 410.05K |
| Aug 11, 2026 | $2.98 | $3.0592 | $2.754 | $3.00 | 487.99K |
| Aug 10, 2026 | $2.83 | $3.10 | $2.66 | $3.04 | 727.31K |
| Aug 7, 2026 | $2.80 | $2.97 | $2.80 | $2.87 | 244.95K |
| Aug 6, 2026 | $2.79 | $2.99 | $2.725 | $2.82 | 387.93K |
| Aug 5, 2026 | $2.84 | $2.84 | $2.70 | $2.81 | 308.52K |
| Aug 4, 2026 | $2.93 | $2.99 | $2.74 | $2.87 | 841.55K |
| Aug 3, 2026 | $2.91 | $3.05 | $2.76 | $2.96 | 1.1M |
| Jul 31, 2026 | $2.95 | $3.20 | $2.92 | $2.99 | 1.06M |
| Jul 30, 2026 | $3.06 | $3.06 | $2.6607 | $2.95 | 1.39M |
Latest ENTX news
The latest Smart Investors Daily articles mentioning ENTX.
Stock researchCompany · Overview
ENTX research
Overview
Company profile and research snapshot.
Company profile
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 9, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | — |
| Oct 7, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 7, 2026
Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise
Entera Bio Q2 loss wider than expected, shares dip 2.5%; FDA accepts Phase 3 plan for EB613 osteoporosis drug, cash runway to 2030.
Yahoo · Aug 7, 2026
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Oversubscribed $275 Million Private Placement Led by BVF Partners L.P. (“BVF”) with Participation from Leading Institutional Healthcare Investors to Fund EB613 through Anticipated Submission of NDA to the FDA EB613 Phase 3 Study Initiation Planned for Late 2026 with Topline Data Anticipated i
Benzinga · Aug 7, 2026
Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half of 2027
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
